2026-04-29T07:35:53Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/230132024-11-28T17:12:04Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16959col_20.500.12105_16967
Repisalud author de Miguel Perez, Diego author Rodriguez Martinez, Alba author Ortigosa Palomo, Alba author Delgado Urena, Mayte author Garcia Puche, Jose Luis author Robles Remacho, Agustin author Exposito Hernandez, Jose author Lorente Acosta, Jose Antonio author Ortega Sanchez, Francisco Gabriel author Serrano, Maria José 2024-09-13T09:15:49Z 2024-09-13T09:15:49Z 2020-03-04 De Miguel Perez D, Rodriguez Martinez A, Ortigosa Palomo A, Delgado Urena M, Garcia Puche JL, Robles Remacho A, et al. Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients. Sci Rep. 2020 Mar 04;10(1):3974. 2045-2322 http://hdl.handle.net/20.500.13003/11409 https://hdl.handle.net/20.500.12105/23013 32132553 10.1038/s41598-020-60212-1 Scientific Reports 2-s2.0-85081239048 563271000005 L631165088 Disseminated disease is present in approximate to 50% of colorectal cancer patients upon diagnosis, being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab, to chemotherapy, has increased progression free survival and overall survival of metastatic colorectal cancer (mCRC) patients. However, these benefits have been only reported in a small proportion of patients. To date, there are not biomarkers that could explain the heterogeneity of this disease and would help in treatment selection. Recent findings demonstrated that microRNAs (miRNAs) play an important role in cancer and they can be encapsulated with high stability into extracellular vesicles (EVs) that are released in biological fluids. EVs can act as cell-to-cell communicators, transferring genetic information, such as miRNAs. In this context, we aimed to investigate serum EV associated miRNAs (EV-miRNAs) as novel non-invasive biomarkers for the diagnosis and prognosis of Bevacizumab-treated mCRC patients. We observed that baseline miRNA-21 and 92a outperformed carcinoembryonic antigen levels in the diagnosis of our 44 mCRC patients, compared to 17 healthy volunteers. In addition, patients who died presented higher levels of miRNA-92a and 222 at 24 weeks. However, in the multivariate Cox analysis, higher levels of miRNA-222 at 24 weeks were associated with lower overall survival. Altogether, these data indicate that EV-miRNAs have a strong potential as liquid biopsy biomarkers for the identification and prognosis of mCRC. eng Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients research article